A carregar...
Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinica...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6372006/ https://ncbi.nlm.nih.gov/pubmed/30804663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S147499 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|